#Germany #Kidney Care #Bad Homburg #Fresenius Medical #ERA Congress

Fresenius Medical Care Presents Innovations in Kidney Care

Fresenius Medical Care (FME) made a significant impact at the 62nd Congress of the European Renal Association (ERA) from June 4-7, 2025, in Vienna, Austria. At this prestigious event, the world's leading provider of products and services for individuals with renal diseases showcased its latest research and innovations, highlighting a commitment to enhancing patient outcomes and quality of life for those affected by kidney issues.

Focus on Data-Driven Insights

The presentations by FME underscore the growing importance of data-driven insights and real-world evidence in kidney care. According to Frank Maddux, MD, Global Chief Medical Officer of Fresenius Medical Care AG, the company's highlighted research reflects its unwavering commitment to innovating in kidney care. The focus areas included Home, Critical Care, and In-Center Hemodialysis, particularly emphasizing high-volume hemodiafiltration as a vital treatment option.

Key Abstract Presentations

Fresenius Medical Care’s Global Medical Office and the Renal Research Institute (RRI) presented 52 abstracts covering critical nephrology areas. Among the standout presentations:
1. Prevalence and Patterns of Intradialytic Arterial Oxygen Saturation Instability: This research, awarded Top Abstract for Young Authors, analyzed AI-driven observations of arterial oxygen saturation during dialysis, revealing insights into intradialytic hypoxemia's potential link to sleep apnea.
2. Health Status in Hemodiafiltration vs. Hemodialysis: A subgroup analysis from the CONVINCE trial explored whether hemodiafiltration leads to an improved self-reported health status compared to hemodialysis, with results indicating enhanced physical and cognitive functions, reduced pain interference, and increased social participation.
3. Fluid Overload and Hospitalization Risk: A study utilizing a validated whole-body bioimpedance spectroscopy device evaluated the impact of changes in fluid overload during dialysis on hospitalization risk over two years.
4. Treatment Time and Mortality Risk in Hemodialysis: This analysis highlighted the connection between shorter treatment times and increased mortality in hemodialysis patients, promoting optimized therapy durations to improve survival outcomes.
5. AI-Based Recipe Recommendation System: Leveraging AI technology, this innovative system offers dialysis patients personalized dietary recommendations, significantly aiding nutritional management.

Engaging with Researchers and Clinicians

Fresenius Medical Care's leaders and researchers were present at Booth #460, engaging with attendees to share insights and foster clinical collaborations aimed at advancing nephrology care. The event served as a pivotal opportunity to build partnerships and drive the future of kidney health.

Fresenius Medical Care Overview

Fresenius Medical Care stands at the forefront of providing services and products for renal disease management, supporting approximately 4.2 million patients globally who undergo dialysis treatment. With a network of 3,675 dialysis clinics worldwide, the company administers critical care to around 299,000 patients and is recognized for its dialysis machines and products on the Frankfurt Stock Exchange (FME) and New York Stock Exchange (FMS).

For further details about Fresenius Medical Care's presence at ERA and its innovative initiatives, please visit Fresenius Medical Care's website.

This event marks a significant milestone for Fresenius Medical Care, underscoring its ongoing pursuit of advancements in kidney care and the well-being of patients worldwide.